Pfizer joins next-gen vaccines R&D consortium

Pfizer ($PFE) has joined the public/private Human Vaccines Project, which is engaged in the hunt for a new generation of vaccines that can tackle cancer, HIV, dengue and more. "Over the last decade, we've seen unprecedented technological advances in our understanding of the biology of diseases, and new tools in designing vaccines including therapeutic vaccines. Yet the translation from preclinical to clinical vaccine research has often been hampered by a lack of understanding of the desired human immune responses required to obtain optimal vaccine protection," said Kathrin Jansen, senior vice president and head of Vaccines Research & Development at Pfizer. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.